Cargando…

Synthesis of [(211)At]4-astato-L-phenylalanine by dihydroxyboryl-astatine substitution reaction in aqueous solution

Astatine-211 ((211)At)-labeled phenylalanine is expected to be a promising agent for targeted alpha-particle therapy for the treatment of patients with glioma. The existing reactions to prepare the labeled compound usually require organic solvents and metals that are toxic and hazardous to the envir...

Descripción completa

Detalles Bibliográficos
Autores principales: Shirakami, Yoshifumi, Watabe, Tadashi, Obata, Honoka, Kaneda, Kazuko, Ooe, Kazuhiro, Liu, Yuwei, Teramoto, Takahiro, Toyoshima, Atsushi, Shinohara, Atsushi, Shimosegawa, Eku, Hatazawa, Jun, Fukase, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217504/
https://www.ncbi.nlm.nih.gov/pubmed/34155314
http://dx.doi.org/10.1038/s41598-021-92476-6
Descripción
Sumario:Astatine-211 ((211)At)-labeled phenylalanine is expected to be a promising agent for targeted alpha-particle therapy for the treatment of patients with glioma. The existing reactions to prepare the labeled compound usually require organic solvents and metals that are toxic and hazardous to the environment. In this study, we developed a novel method wherein astatination was realized via the substitution of (211)At for a dihydroxyboryl group coupled to phenylalanine. [(211)At]4-astato-L-phenylalanine was obtained as the carrier-free product in aqueous medium in high radiochemical yields (98.1 ± 1.9%, n = 5). The crude reaction mixture was purified by solid-phase extraction, and the radiochemical purity of the product was 99.3 ± 0.7% (n = 5). The high yield and purity were attributed to the formation of [(211)At]AtI and AtI(2)(−) as the reactive intermediates in the astatination reaction. The reaction did not require any organic solvents or toxic reagents, suggesting that this method is suitable for clinical applications.